ADV912: A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma


Leukemias / Lymphomas : Relapses/refractory solid tumors and anaplastic large cell lymphoma


This is a Phase 1/2 study of a drug called PF-02341066. PF-02341066 is a drug that in laboratory studies can block or inhibit two proteins called c-met and Alk. These proteins may be important in the growth of certain types of cancer cells. PF-02341066 is considered experimental because the Food and Drug Administration (FDA) have not approved it.

The purpose of such studies (Phase I studies) is to find the largest dose of the drug that can be given safely to children and young adults, and to learn what its side effects are. This study uses PF-02341066 because it seems to work against cancer in test tubes and animals. The study teams of doctors do not know if PF-02341066 will work in children. PF-02341066 has been used in only a small number of adults. There is no guarantee that research participants who take part in this study will benefit from the experimental treatment.



For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE  (1-866-278-5833).


John Sandlund, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.